News

Stay up to date with the latest activity at Richmond Pharmacology

COVID-19 – External Monitoring Guidelines

1
July 2020

Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.

View article

Statement: COVID-19

23
March 2020

Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.

View article

First transdermal patch to treat schizophrenia hits market

18
March 2020

The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful

View article

Richmond Pharmacology supporting clinical facilities in Nicaragua

30
January 2020

Richmond Pharmacology have developed a resourceful way to use study equipment to help reduce waste produced on site and support clinical facilities in under developed nations.

View article

Charitable Contributions in 2019

2
January 2020

As the 2019 year comes to an end, we would like to recognize the substantial charitable contributions made by the Richmond Pharmacology team; including our staff, academic

View article

Richmond Pharmacology to provide Immediate Life Support (ILS) Courses

31
July 2019

In line with our on-going commitment to providing quality training and promoting the highest safety standard, Richmond Pharmacology are pleased to announce that our ILS

View article

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more